Event time: 事件时间：
Published: 文章发布：
Key Results
Actual vs Consensus
EPS: $3.96 vs $3.73 estimate, beat+6.2%.Revenue: $1.2B vs $1.2B estimate, beat+1.9%.Profitability and Cash Flow
Period: 2026 Q3 period ended 2026-09-30Revenue: $1.2B; YoY: +9.9%; QoQ: -0.2%Gross profit: $764M; Gross margin: 62.9%Operating income: $402M; Operating margin: 33.1%; YoY: +13.4%; QoQ: -5.5%Net income: $317M; GAAP diluted EPS: $0.00; YoY: +15.5%; QoQ: -6.3%Operating cash flow: $450M; Capex: $29M; Free cash flow: $421MOfficial release: IDEXX Laboratories Announces Third Quarter Results
核心结果
实际值与市场预期
EPS：$3.96 vs $3.73 预期，高于预期+6.2%。营收：$1.2B vs $1.2B 预期，高于预期+1.9%。财务指标
期间：2026 Q3（截至 2026-09-30）营收：$1.2B；同比：+9.9%；环比：-0.2%毛利润：$764M；毛利率：62.9%经营利润：$402M；经营利润率：33.1%；同比：+13.4%；环比：-5.5%净利润：$317M；GAAP 稀释 EPS：$0.00；同比：+15.5%；环比：-6.3%经营现金流：$450M；资本开支：$29M；自由现金流：$421M
